# Heart Failure Classification based on Objective Measurement Data

Published: 02-06-2017 Last updated: 15-05-2024

The primary objective of this study is to develop an objective, clinical relevant classification model of disease severity for patients with HF based on an extensive, complete dataset of

patients with HF.

**Ethical review** Approved WMO

**Status** Recruitment stopped

**Health condition type** Heart failures

**Study type** Observational non invasive

## **Summary**

### ID

NL-OMON45646

#### Source

**ToetsingOnline** 

#### **Brief title**

HaFaC study

#### **Condition**

Heart failures

## **Synonym**

Cardiac Decompensation, Heart Failure

#### Research involving

Human

## **Sponsors and support**

**Primary sponsor:** Catharina-ziekenhuis

Source(s) of monetary or material Support: Catharina Ziekenhuis Eindhoven

Intervention

**Keyword:** Classification, Data Mining, Heart Failure

**Outcome measures** 

**Primary outcome** 

Main study parameters are echocardiographic structural and functional measures,

blood marker levels, QOL scores, 6MWT (and when measured (spiro-)ergometry)

performance scores, (24 hour) ECG-derived variables, 24 hour blood pressure

measurements, and PPG and accelerometer data of patients with HF.

The main study endpoint is an objective classification model for HF patients

where the model output is represented as a scale of HF disease severity

reflected by clinically relevant, objective measures. The study endpoint for

the participant is the composite endpoint of all-cause mortality, heart

transplantation or Left Ventricular Assist Device (LVAD) implantation.

**Secondary outcome** 

Secondary endpoints are:

expert-based NYHA classification

questionnaire-based NYHA classification

QOL (MLHFQ and SF-36 questionnaires)

structural and functional characteristics of the heart through

echocardiography (e.g. left ventricular dimensions and LVEF)

• biomarker levels (e.g. NT-proBNP)

simultaneous registered ECG and blood pressure signals and consequential

characteristics (e.g. heart rate variability)

2 - Heart Failure Classification based on Objective Measurement Data 24-05-2025

- PPG and accelerometer signals
- exercise tolerance according to 6MWT and (spiro-)ergometry (e.g. percentage capacity)
- hospitalization for HF
- LVAD implantation
- heart transplantation
- mortality

# **Study description**

## **Background summary**

Heart failure (HF) is a complex clinical syndrome of signs and symptoms due to a structural or functional abnormality of the heart leading to inadequate pumping function. The functional state of the patient, i.e. the ability to do the daily activities, plays an important role in HF. Classification of HF using the New York Heart Association (NYHA) is based on symptoms and perception of exercise tolerance. In addition to the assessment of severity of the symptoms upon diagnosis, the NYHA classification is also used to monitor response to treatment and is a predictor of mortality. Although the NYHA classification itself has proved to be clinically useful, the way of classifying HF patients, based on the patient\*s and physician\*s perception of exercise intolerance, is inaccurate. Therefore, a need is seen in a new classification model for HF patients which is based on multiple, objective, and clinically relevant measures covering multiple aspects of the HF syndrome.

## Study objective

The primary objective of this study is to develop an objective, clinical relevant classification model of disease severity for patients with HF based on an extensive, complete dataset of patients with HF.

## Study design

The study is a prospective, non-randomized, observational, single-center study.

## Study burden and risks

In this study, 278 patients will be included that represent a cross-section of the outpatient heart failure patient population in the Cardiology department of the Catharina Hospital. All of these patients will undergo multiple measurements at the Catharina Hospital during the patient\*s outpatient visit, i.e. echocardiography, blood withdrawal for biomarker level analysis, and QOL assessment through questionnaires. Additionally, in a subgroup of participants ergometry or spirometry and simultaneous ECG, blood pressure, PPG and accelerometer data of participating patients will be collected.

The risks associated with this study are negligible. The study consists of measurements that are part of standard clinical care. Only the combination of all the measurements is unusual in the outpatient clinical care. Since the data obtained by this study may result in a method to classify and monitor patients with heart failure in an objective manner in the future, and since the manner in which the data is obtained is identical to already delivered standard care (whether or not in the combination, as done in this study), we believe that this research is warranted.

## **Contacts**

#### **Public**

Catharina-ziekenhuis

Michelangelolaan 2 Eindhoven 5623 EJ NI

Scientific

Catharina-ziekenhuis

Michelangelolaan 2 Eindhoven 5623 EJ NL

# **Trial sites**

#### **Listed location countries**

**Netherlands** 

# **Eligibility criteria**

#### Age

Adults (18-64 years) Elderly (65 years and older)

#### Inclusion criteria

In order to be eligible to participate in this study, a subject must have (suspected) heart failure (based on ESC guidelines 2016), is scheduled for a cardiac ultrasound, has not had cardiothoracic surgery within 90 days prior to moment of inclusion, must have the minimum age of 18 years, and must be able to provide informed consent.

## **Exclusion criteria**

A potential subject will be excluded from the study if the patient is pregnant or when the subject has terminal heart failure with a life expectancy of several weeks.

# Study design

## **Design**

**Study type:** Observational non invasive

Masking: Open (masking not used)

Control: Uncontrolled

Primary purpose: Other

## Recruitment

NL

Recruitment status: Recruitment stopped

Start date (anticipated): 07-12-2017

Enrollment: 278

Type: Actual

## **Ethics review**

Approved WMO

Date: 02-06-2017

Application type: First submission

Review commission: MEC-U: Medical Research Ethics Committees United

(Nieuwegein)

Approved WMO

Date: 01-05-2018

Application type: Amendment

Review commission: MEC-U: Medical Research Ethics Committees United

(Nieuwegein)

Approved WMO

Date: 30-09-2021

Application type: Amendment

Review commission: MEC-U: Medical Research Ethics Committees United

(Nieuwegein)

# **Study registrations**

## Followed up by the following (possibly more current) registration

No registrations found.

## Other (possibly less up-to-date) registrations in this register

ID: 28510

Source: Nationaal Trial Register

Title:

## In other registers

Register ID

CCMO NL60579.100.17 OMON NL-OMON28510